Efficacy and adverse effets of nimotuzumab plus palitaxel liposome and carboplatin in the treatment for advanced non-small cell lung cancer

Chinese Journal of Oncology

Volumn 34, Issue 2, 2012, Pages 152-155

  Qi, Da Liang ^a   Wang, Hua Qing ^b   Li, Yan ^b   Huang, Chong Biao ^b   Wang, Qing Sheng ^b   Xu, Jie ^b   Yang, Yan Zhuo ^b   Cui, Yan ^b   Xin, Liang ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Carcinoma, non small cell lung; Drug therapy, combination; Nimotuzmab; Treatment outcome

Indexed keywords

CARBOPLATIN; NIMOTUZUMAB; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 84863355175     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2012.02.016     Document Type: Article

References (10)

1. Akashi Y, Okamoto I, Iwasa T, et al. Enhancement of the antitumor activity of ionizing radiation by nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer, 2008, 98:749-755. (Pubitemid 351272610)
2. Socinski MA. Antibodies to be epidermal growth factor receptor in non-small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res, 2007, 13:s4597-s4601.
3. Gridelli C, Maione P, Ferrera ML, et al. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist, 2009, 14:601-611.
4. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/AKt pathway for proliferation. Mol Cancer Ther, 2004, 3:465-472. (Pubitemid 39193724)
5. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep, 2008, 41:615-625
6. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 2007, 25:5777-5784.
7. Spigel DR, Greco FA, Thompson DS, et al. Phase II study of cetuximab, docetaxel, and gemcitabine in patients with perviously untreated advanced non-small cell lung cancer. Clin Lung Cancer, 2010, 1:198-203.
8. Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist, 2005, 10:760-761. (Pubitemid 41567290)
9. Rojo F, Gracias E, Villena N, et al. Pharmacodynamic trial of Nimotuzumab in unresectable squamous cell carcinoma of head and neck: a SENDO Foundation study. Clin Cancer Res, 2010, 16:2474-2482.